N-methyl-8-(3-pyridin-2-ylpyrrolidine-1-carbonyl)-2-thiophen-3-ylimidazo[1,2-a]pyridine-3-carboxamide
C23H21N5O2S — CID 143716777
Data last refreshed: (MolForge compound catalog, from PubChem)
About N-methyl-8-(3-pyridin-2-ylpyrrolidine-1-carbonyl)-2-thiophen-3-ylimidazo[1,2-a]pyridine-3-carboxamide
N-methyl-8-(3-pyridin-2-ylpyrrolidine-1-carbonyl)-2-thiophen-3-ylimidazo[1,2-a]pyridine-3-carboxamide (PubChem CID 143716777) has the molecular formula C23H21N5O2S and a molecular weight of 431.52 g/mol. Its IUPAC name is N-methyl-8-(3-pyridin-2-ylpyrrolidine-1-carbonyl)-2-thiophen-3-ylimidazo[1,2-a]pyridine-3-carboxamide.
Molecular Properties
| Compound Name | N-methyl-8-(3-pyridin-2-ylpyrrolidine-1-carbonyl)-2-thiophen-3-ylimidazo[1,2-a]pyridine-3-carboxamide |
|---|---|
| PubChem CID | 143716777 |
| Molecular Formula | C23H21N5O2S |
| Molecular Weight | 431.52 g/mol |
| Exact Mass | 431.14 |
| IUPAC Name | N-methyl-8-(3-pyridin-2-ylpyrrolidine-1-carbonyl)-2-thiophen-3-ylimidazo[1,2-a]pyridine-3-carboxamide |
| SMILES | CNC(=O)c1c(-c2ccsc2)nc2c(C(=O)N3CCC(c4ccccn4)C3)cccn12 |
| InChI | InChI=1S/C23H21N5O2S/c1-24-22(29)20-19(16-8-12-31-14-16)26-21-17(5-4-10-28(20)21)23(30)27-11-7-15(13-27)18-6-2-3-9-25-18/h2-6,8-10,12,14-15H,7,11,13H2,1H3,(H,24,29) |
| InChIKey | HFAOLTWGRGMNDN-UHFFFAOYSA-N |
| XLogP | 3.45 |
| TPSA | 79.60 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 6 |
| Rotatable Bonds | 4 |
| Heavy Atoms | 31 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 431.52 |
| LogP ≤ 5 | 3.45 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 6 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 143716777 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.